4.7 Article

A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis

期刊

EMBO MOLECULAR MEDICINE
卷 6, 期 8, 页码 1062-1074

出版社

WILEY
DOI: 10.15252/emmm.201403856

关键词

biliary ductular reaction; Caspase-8; liver fibrosis; MCP-1; necroptosis

资金

  1. German-Research-Foundation [SFB-TRR57/P06, SFB-TR36]
  2. German Cancer Aid [Deutsche Krebshilfe 110043]
  3. ERC Starting Grant [ERC-2007-Stg/208237-Luedde-Med3-Aachen]
  4. EMBO Young Investigator Program
  5. Ernst-Jung-Foundation/Hamburg
  6. Interdisciplinary-Centre-for-Clinical-Research (IZKF)
  7. medical faculty of the RWTH Aachen
  8. Helmholtz Foundation
  9. Hofschneider Foundation
  10. Helmholtz alliance preclinical comprehensive center (PCCC)
  11. ERC Starting grant (LiverCancerMechanisms)
  12. Deutsche Stiftung Herzforschung [12/12]

向作者/读者索取更多资源

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease in Western countries and often progresses to non-alcoholic steatohepatitis (NASH) leading ultimately to liver fibrosis and liver cancer. The occurrence of hepatocyte cell deathso far characterized as hepatocyte apoptosisrepresents a fundamental step from benign steatosis toward progressive steatohepatitis. In contrast, the function of RIP3-dependent necroptosis in NASH and NASH-induced fibrosis is currently unknown. We show that RIP3 is upregulated in human NASH and in a dietary mouse model of steatohepatitis. RIP3 mediates liver injury, inflammation, induction of hepatic progenitor cells/activated cholangiocytes, and liver fibrosis through a pathway suppressed by Caspase-8. This function of RIP3 is mediated by a positive feedback loop involving activation of Jun-(N)-terminal Kinase (JNK). Furthermore, RIP3-dependent JNK activation promotes the release of pro-inflammatory mediators like MCP-1, thereby attracting macrophages to the injured liver and further augmenting RIP3-dependent signaling, cell death, and liver fibrosis. Thus, RIP3-dependent necroptosis controls NASH-induced liver fibrosis. This pathway might represent a novel and specific target for pharmacological strategies in patients with NASH.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据